Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.
Wasif M. Saif, MD, deputy physician in chief at Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses available novel therapies for treating hepatocelluclar carcinoma (HCC) in the second-line setting.
HCC is a heterogenous disease and difficult to treat, according to Saif, but there are now multiple agents available to treat patients who have failed first-line therapy, including 3 targeted agentsregorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza)—and 2 immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda). However, there are no randomized data to inform oncologists which patient is right for each agent.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More